_petra-next-generation-parp1-selective-inhibitor-azd5305-in-patients-with-brca1-2-palb2-or-rad51c-d-mutations.jpg "PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1 2, PALB2 or RAD51C D mutations from parp Video Screenshot Preview")
GalleryPlay Video:
(Note: The default playback of the video is HD VERSION. If your browser is buffering the video slowly, please play the REGULAR MP4 VERSION or Open The Video below for better experience. Thank you!)
⏲ Duration: 2 min 70 sec
✓ Published: 11-Apr-2022
✓ Published: 11-Apr-2022
Description:
Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar
Dr Timothy Yap speaks to ecancer about the PETRA trial that he presented at the AACR 2022 meeting. The trial was a first in class, first in human trial of the next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations.nnHe reports that the results showed that AZD5305 successfully improved safety and showed promising clinical activity.nnDr Yap believes that this is proof of concept in the clinic for this innovative strategy and that expansion trials ar
Share with your friends:
Whatsapp | Viber | Telegram | Line | SMS
Email | Twitter | Reddit | Tumblr | Pinterest
Related Videos
_windy-out.webp "A stupid video to go with the song by AJ Cookson in which he sampled loads of his farts that he had recorded onto his mobile phone. how charming.")
_sabcs-2017-phase-iii-embraca-trial-comparing-talazopari-to-physician39s-choice-of-therapy-meets-primary-endpoint.webp "SABCS 2017: Phase III EMBRACA Trial Meets Primary EndpointnGS6-07. Litton J, Rugo HS, Ettl J, Hurvitz S, et al. EMBRACA: A phase 3 trial comparing talazoparib, an oral PARP inhibitor, to physician's choice of therapy in patients with advanced breast cancer and a germline BRCA mutation.nPresented at the San Antonio Breast Cancer Symposium Press Conference, December 8 - More Info: http://oncoletter.ch")
⏲ 9 min 35 sec ✓ 08-Dec-2017
_tropicana-39parp39.webp "Direction /// Jens & AnnanProd. Company /// Picasso PicturesnExec. Producer /// Inga JohnsonnCharacter Design /// Jens & AnnannAgency /// AMV BBDOnClient /// PepsiConnVFX supervisor /// Bence VargannModelling /// David Kent, Sergei ShabarovnRigging /// Sergei ShabarovnAnimation /// Aurel Duhayon, Juliette CoutelliernSimulation /// Eaton CrousnLighting & Rendering /// Benoit Berthe Siward, Kevin RussellnnCompositing Lead /// Bence VarganCompositing /// Ernesto Herrmann, Arnaud Dumeyni")
_stories-of-innovation-preact.webp "Historically, more than 75% of ovarian cancers would eventually recur, at which point they are not curable. But recent FDA approvals for a new class of oral drugs called parp inhibitors have resulted in significantly improved survival for newly diagnosed ovarian cancer patients.nnHowever, the effectiveness of these treatments is dependent on genetic and tumor mutations. A complex process of multiple genetic and tumor tests, each of which can take weeks to complete, must be completed within fou")
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.webp "Dr Neal Shore speaks to Prof Karim Fizazi about the changing landscape of treatments for prostate cancer, discussing immunotherapies, PARP inhibitors and PSMA testing as future targets and treatments.nnDr Fizazi highlights that anti-PD1 treatment (pembrolizumab) may provide benefit for metastatic castration resistant patients following antiandrogen treatment (5 of the 28 patients in the trial had a PSA decline of50%). nnTrials building on immune checkpoint therapies with novel combinations to")
_anthony-d-elias-md-on-triple-negative-breast-cancer-parp-inhibitors-in-the-current-treatment-landscape.webp "Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews new NCCN recommendations for PARP inhibitor therapy in TNBC and the implications of the now-approved olaparib for gBRCA-mutant breast cancer.")
⏲ 2 min 25 sec ✓ 24-Mar-2018
_inhibitor-by-ed-carter.webp "Researchers at the Northern Institute for Cancer Research (NICR) have played a central role in the development of PARP Inhibitors – a targeted treatment that kills cancer cells, while leaving healthy cells relatively unscathed. The first cancer patient in the world to be given this new type of drug was treated in Newcastle in 2003.nnIn response to this incredible research, Ed Carter has worked closely with the NICR team over a number of months to create “Inhibitor”.nnVisually, a series of")
_comparing-parp-inhibitors.webp "Dr Leo speaks with ecancer about results from a head-to-head comparison of five PARP inhibitors. nnHaving compared the approvals, mechanisms and doses of olaparib, veliparib, rucaparib, niraparib and talazoparib, Dr Leo highlights the potential for predicting responses and assessing novel PARP inhibitors.nnFor more on PARP inhibitors, watch our interview with Dr Mark O’Connor here.nnSign up to ecancer for free to receive tailored email alerts for more videos like this.nnhttps://ecancer.org/acc")
_windy-out.jpg)
_sabcs-2017-phase-iii-embraca-trial-comparing-talazopari-to-physician39s-choice-of-therapy-meets-primary-endpoint.jpg)
_tropicana-39parp39.jpg)
_stories-of-innovation-preact.jpg)
_asco-2018-novel-treatment-strategies-in-prostate-cancer-therapeutics.jpg)
_anthony-d-elias-md-on-triple-negative-breast-cancer-parp-inhibitors-in-the-current-treatment-landscape.jpg)
_inhibitor-by-ed-carter.jpg)
_comparing-parp-inhibitors.jpg)
![[+]](/images/menu.gif){kind=small}